Last reviewed · How we verify
Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine
Popular topic：Clinical study of recombinant Novel Coronavirus vaccine (CHO cell) combined with influenza vaccine. Research purpose:Main purpose:To evaluate the immunogenicity of recombinant Novel Coronavirus vaccine (CHO cells) combined with influenza vaccine in people aged 18 years and over. Secondary purpose:To evaluate the safety of recombinant Novel Coronavirus vaccine (CHO cells) combined with influenza vaccine in people aged 18 years and over. Overall design:An open experimental design was adopted in this study, and 300 subjects were planned to be enrolled. To evaluate the immunogenicity and safety of recombinant Novel Coronavirus vaccine (CHO cells) in combination with influenza vaccine. Study population:The study involved people 18 years of age and older. Test groups:A total of 300 cases were enrolled. 240 patients in 18-59 years old group, 60 patients in ≥60 years old group. There were 150 cases in group A, 120 cases in 18-59 years old group, and 30 cases in ≥60 years old group. There were 150 cases in group B, 120 cases in 18-59 years old group and 30 cases in ≥60 years old group.
Details
| Lead sponsor | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
|---|---|
| Phase | PHASE3 |
| Status | COMPLETED |
| Enrolment | 299 |
| Start date | Fri Sep 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Mar 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Coronavirus Disease 2019
Interventions
- Tetravalent influenza virus lysis vaccine
- Recombinant new coronavirus vaccine (CHO cell) group
Countries
China